In Vilnius, Lithuania, a pivotal moment was marked with the first topping-out ceremony at the BIO CITY complex, a project developed by the Northway Healthcare Group. This event signifies substantial progress in constructing what is set to be Europe's largest biotechnology city. The Gene Therapy Center, a cornerstone of this complex, is steadily advancing towards its completion.
Prof. Vladas Algirdas Bumelis, the founder of Northway, commented on the construction's smooth progress, which is in line with the original plans. "We are committed to adhering to our schedule for 2024. At our new facility, we are eager to begin developing both new and existing innovative technologies for gene therapy product manufacturing," he stated.
The Gene Therapy Center, set to be completed this year, will play a pivotal role in strengthening Lithuania's regional and global leadership in the development and application of gene engineering. The center will conduct cutting-edge gene therapy research and cGMP manufacturing, with an investment of 50 million euros, creating over 100 high-value jobs.
BIO CITY is a project led by Northway Group, with subsidiary companies that include the biologics CDMO Northway Biotech and Celltechna. By 2030, BIO CITY has plans to unveil five additional complexes, featuring facilities including the R&D and Virology Centre, Life Science Industry Hub Smart Service Centre, Large-Scale Microbial Production Centre, Large-Scale Mammalian Production Centre, and Stem Cell Research and 3D Bioprinting Centre. The entire BIO CITY complex will span an area equivalent to 10 football fields, with the total investment expected to reach approximately 7 billion euros over the next decade. For more information, please visit https://biocity.lt.
BIO CITY Contacts:
Vladas Algirdas Bumelis
CEO and Chairman of the Board
Press release PDF
Please find our press release offered for download in a PDF form below: